Pretreatment of NLRP3-/- and AIM2-/- BMDCs with IFN-I receptor blocking antibody led to a marked increase in IL-1β (Fig 6B) and IL-17 (Fig 6C) production, demonstrating a novel mechanism by which IFN-I signaling regulates inflammation in schistosomiasis. Here, NLRP3 is linked to schistosomiasis.